Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial-Reference-Cited by-同舟云学术

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

Published:2017-09-21 Issue:1 Volume:7 Page:e1372081
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Chung David J.¹²³⁴⁵,Carvajal Richard D.⁶⁷⁴⁵⁸,Postow Michael A.⁶⁷⁴⁵⁸,Sharma Sneh¹⁵,Pronschinske Katherine B.¹⁵,Shyer Justin A.¹⁵,Singh-Kandah Shahnaz⁶⁷⁴⁵,Dickson Mark A.⁹⁷⁴⁵⁸,D'Angelo Sandra P.⁹⁷⁴⁵⁸,Wolchok Jedd D.⁶⁷⁴⁵¹⁰,Young James W.¹²³⁴¹¹

Affiliation:

1. Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY

2. Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

3. Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

5. Memorial Sloan Kettering Cancer Center, New York, NY

6. Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY

7. Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

8. Weill Cornell Medical College, New York, NY, USA

9. Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY

10. The Rockefeller University, New York, NY

11. Immunology Program, Sloan Kettering Institute for Cancer Research

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1372081

Reference41 articles.

1. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

2. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

3. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

4. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

5. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Langerhans Cells in Sentinel Lymph Nodes from Melanoma Patients;Cancers;2024-05-16

2. Dendritic Cells in Cancer Immunology and Immunotherapy;Cancers;2024-02-28

3. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy;Trends in Immunology;2024-01

4. Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy;ACS Applied Bio Materials;2023-11-06

5. Amplifying mRNA vaccines: potential versatile magicians for oncotherapy;Frontiers in Immunology;2023-10-23